STAT3磷酸化抑制治疗强直性脊柱炎的炎症与新骨形成
本研究评估STAT3磷酸化抑制剂(stat3-p Inh)能否同时治疗强直性脊柱炎(AS)的慢性炎症和骨形成。在SKG小鼠模型中,stat3-p Inh显著抑制关节炎、附着点炎、脊柱炎和回肠炎;体外实验显示其减少AS患者SFMCs和LPMCs中IFN-γ、IL-17A和TNF-α产生细胞频率;Micro-CT显示stat3-p Inh治疗组后爪新骨形成少于vehicle组(P=0.005),与抗IL-17A治疗组相似(P=0.874和P=0.117)。结论认为STAT3磷酸化抑制是AS炎症和新骨形成的有前景治疗。
要点
- stat3-p Inh在SKG小鼠中抑制关节炎、附着点炎、脊柱炎和回肠炎。
- stat3-p Inh减少AS患者SFMCs和LPMCs中IFN-γ、IL-17A和TNF-α产生细胞频率。
- stat3-p Inh减少小鼠后爪新骨形成(P=0.005),与抗IL-17A效果相似。
核心结论
- STAT3磷酸化抑制是同时治疗AS炎症和新骨形成的有前景方法。
研究设计与样本
- 研究检测了原代AS骨祖细胞和脊柱附着点细胞的成骨分化,并分析了AS患者SFMCs和LPMCs。
- 雌性SKG小鼠分别接受stat3-p Inh、IL-17A阻断剂或vehicle治疗,通过免疫组化、PET和micro-CT评估炎症和新骨形成。
主要发现
- 在SKG小鼠模型中,stat3-p Inh显著抑制关节炎、附着点炎、脊柱炎和回肠炎。
- 培养SFMCs和LPMCs实验中,stat3-p Inh处理后产生IFN-γ、IL-17A和TNF-α的细胞频率显著降低。
- 与JAK抑制剂或IL-17A阻断剂相比,stat3-p Inh对AS骨祖细胞成骨显示 comparable 抑制效果。
- stat3-p Inh抑制AS骨祖细胞和附着点细胞向成骨细胞的分化和矿化。
- Micro-CT分析显示stat3-p Inh治疗小鼠后爪新骨形成少于vehicle治疗小鼠(P=0.005)。
关键数值与推荐
- 后爪和脊柱新骨形成在stat3-p Inh与抗IL-17A治疗的SKG小鼠间相似(P=0.874和P=0.117)。
临床怎么用
- STAT3磷酸化抑制可能作为AS同时控制炎症和新骨形成的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: AS is a rheumatic disease characterized by chronic inflammation and bony ankylosis. This study was to evaluate whether a signal transducer and activator of transcription 3 phosphorylation inhibitor (stat3-p Inh) could treat both chronic inflammation and bone formation in AS. METHODS: Primary AS osteoprogenitor cells and spinal entheseal cells were examined for osteogenic differentiation. SF mononuclear cells (SFMCs) and lamina propria mononuclear cells (LPMCs) were obtained from AS patients. Inflammatory cytokine-producing cells were analysed using flow cytometry and ELISA. Female SKG mice were treated with stat3-p Inh, IL-17A blocker or vehicle. Inflammation and new bone formation were evaluated using immunohistochemistry, PET and micro-CT. RESULTS: In the SKG mouse model, stat3-p Inh significantly suppressed arthritis, enthesitis, spondylitis and ileitis. In experiments culturing SFMCs and LPMCs, the frequencies of IFN-γ-, IL-17A- and TNF-α-producing cells were significantly decreased after stat3-p Inh treatment. When comparing current treatments for AS, stat3-p Inh showed a comparable suppression effect on osteogenesis to Janus kinase inhibitor or IL-17A blocker in AS-osteoprogenitor cells. Stat3-p Inh suppressed differentiation and mineralization of AS-osteoprogenitor cells and entheseal cells toward osteoblasts. Micro-CT analysis of hind paws revealed less new bone formation in stat3-p Inh-treated mice than vehicle-treated mice (P = 0.005). Hind paw and spinal new bone formation were similar between stat3-p Inh- and anti-IL-17A-treated SKG mice (P = 0.874 and P = 0.117, respectively). CONCLUSION: Stat-3p inhibition is a promising treatment for both inflammation and new bone formation in AS.
引用
- Jo S, Won EJ, Kim MJ, et al. STAT3 phosphorylation inhibition for treating inflammation and new bone formation in ankylosing spondylitis. Rheumatology (Oxford). 2021. PMID: 33237331. doi:10.1093/rheumatology/keaa846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。